GLOW is a research blend of three peptides, GHK-Cu, BPC-157 and TB-500, studied mainly for tissue repair, skin remodeling and recovery. It gets attention because each of the three works on a different stage of the same repair process, so the blend covers ground that no single peptide covers alone.
The three also sit at very different points on the evidence ladder, and that gap is the part most GLOW articles skip. One is a molecule your own blood already carries and has been measured in patients. One has a parent compound that reached phase 2 human trials. One has a research base that is broad, consistent and almost entirely preclinical.
One thing to establish up front. GLOW isn’t a dietary supplement. It’s a research preparation, supplied to laboratories rather than sold on a shelf, and you won’t find it on this site. This article covers what the science says about the three peptides inside it, and which of those findings connect to something you can actually take.
Key Takeaways
The Short Version
GLOW is a research-use blend of GHK-Cu, BPC-157 and TB-500, studied for tissue repair, skin remodeling and recovery support.
GHK-Cu carries the strongest human evidence of the three, including controlled studies on aged skin and blood levels that fall measurably with age.
BPC-157 has the deepest animal research base, with 35 of the 36 studies in a 2025 systematic review conducted in preclinical models.
TB-500 is a synthetic fragment of thymosin beta-4, a human peptide that reached phase 2 trials for dry eye and chronic wounds.
What Is the GLOW Peptide Blend?
GLOW is the informal name for a combination of three peptides, GHK-Cu, BPC-157 and TB-500, prepared together instead of handled separately. It isn’t one company’s branded product. It’s a grouping the peptide research world settled on, which is why you’ll see the same three names under the GLOW label from different suppliers.
The three are grouped for a reason worth understanding, because it’s the whole logic of the blend.
Tissue repair isn’t one event. It’s a sequence: the right cells have to reach the damaged area, they have to survive and stay active once they get there, and they have to lay down new structural material. Each of the three peptides has been studied against a different part of that sequence.
| Peptide | What it is | What it’s studied for in the blend |
|---|---|---|
| GHK-Cu | A three amino acid human peptide bound to copper | Collagen and elastin synthesis, skin remodeling |
| BPC-157 | A fifteen amino acid fragment from a gastric juice protein | Fibroblast activity and connective tissue repair |
| TB-500 | A synthetic fragment of thymosin beta-4 | Cell migration and reduced scarring |
That’s the case for combining them. No single one of the three covers the full sequence, so the blend is an attempt to cover more of it at once.
A few practical things a newcomer should know. GLOW is supplied as a freeze-dried powder that has to be mixed with liquid before use, and it’s used by injection rather than swallowed. It’s classified as a research preparation, not a dietary supplement, which means it hasn’t been through the review a consumer product goes through and isn’t sold for personal use.
There’s a closely related blend called KLOW that adds a fourth peptide, KPV, to the same three. Our side by side breakdown of KLOW and GLOW covers what that fourth ingredient changes.
Nothing here is a protocol. If you want the underlying biology first, how peptide signaling works is the place to start.
GHK-Cu, the Peptide Your Blood Carries Less of Every Decade
GHK-Cu is the component with the most human data behind it, and it’s the reason GLOW gets talked about for skin. GHK occurs naturally in human serum, and it binds copper with very high affinity to form the GHK-Cu complex.
Here’s the number that frames everything else. Human serum GHK averages around 200 ng/ml at age 20 and falls to roughly 80 ng/ml by age 60, a decline of about 60% across four decades of adult life. Researchers have proposed that this drop is part of why tissue repair slows with age.
The topical evidence is where GHK-Cu stops being theoretical. Controlled studies in aged skin have found that GHK-Cu tightens skin, improves elasticity and firmness, and reduces fine lines, wrinkles, photodamage and hyperpigmentation. That’s real human cosmetic data, which puts GHK-Cu in a different category from most peptides in this space.
The mechanism work explains why. A review built on gene profiling data describes GHK-Cu increasing synthesis of collagen, elastin and glycosaminoglycans, supporting dermal fibroblast function, and stimulating blood vessel and nerve outgrowth. The same work reports it influencing a large number of human genes rather than acting on one narrow pathway.
Its biology also reaches past the skin. A 2023 study in the Journal of Cachexia, Sarcopenia and Muscle measured plasma GHK in patients with chronic obstructive pulmonary disease and found levels averaging 70 ng/ml against 133 ng/ml in healthy age-matched subjects, with the difference tracking pectoralis muscle area and inflammatory markers. The same researchers showed in cell and mouse work that GHK-Cu activates SIRT1, a longevity-associated enzyme.
So GHK-Cu does double duty in GLOW. It carries the skin story, and it’s the one component with a measured human baseline.
What the BPC-157 Research Base Looks Like
BPC-157 is the repair signal in the blend, and its research base is broad, consistent and honest about what it is. A 2025 systematic review in orthopaedic sports medicine screened 544 articles and included 36 studies, of which 35 were preclinical and one was clinical.
That single clinical study is worth naming. It was a retrospective look at intraarticular BPC-157 for chronic knee pain, where 7 of 12 patients reported relief lasting more than six months. It’s small and uncontrolled, and it’s still the most human evidence BPC-157 has on record.
The preclinical volume is what makes the case. Across rodent models, the same review reports BPC-157 improving functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone injuries, while increasing growth hormone receptor expression and lowering inflammatory cytokines.
The cell-level work shows how it might do that. In research on tendon explants and cultured fibroblasts, BPC-157 accelerated fibroblast outgrowth, improved cell survival under oxidative stress, and increased fibroblast migration in a dose-dependent way through the FAK-paxillin pathway. Migration matters because repair depends on the right cells reaching the injury.
A review of the musculoskeletal soft tissue literature describes those healing effects as consistent across injury types and tissue types, with few studies reporting adverse reactions. It also notes how much of that work sits in small rodent models, with human confirmation still ahead of it.
One material point for athletes. BPC-157 is on the World Anti-Doping Agency prohibited list, so anyone subject to drug testing should avoid it in any form. If your question is about oral formats rather than injection, our piece on whether BPC-157 capsules work covers the route question in detail.
TB-500 and the Human Trials Most Articles Miss
TB-500 has the most surprising evidence file of the three, because its parent molecule has been through real human trials. TB-500 is a synthetic fragment of thymosin beta-4, a small peptide found inside most vertebrate cells and released by platelets at the site of an injury.
Thymosin beta-4 has a clear job in the body. Work on its basic properties and clinical applications describes it as the main intracellular actin-sequestering peptide, and outside the cell it promotes cell migration, mobilizes stem and progenitor cells, and reduces the number of myofibroblasts in a healing wound, which lowers scar formation and fibrosis.
The human trial data is specific. In a phase 2 randomized, double-masked, placebo-controlled trial in severe dry eye disease, thymosin beta-4 eye drops produced a 35.1% reduction in ocular discomfort and a 59.1% reduction in total corneal fluorescein staining against vehicle control at day 56. Both results were statistically significant.
It has been tested on skin too. Thymosin beta-4 accelerated repair in phase 2 trials in patients with pressure ulcers, venous stasis ulcers and epidermolysis bullosa wounds, and was reported as safe and well tolerated. A separate double-blind, placebo-controlled dose-escalation study across sites in Italy and Poland evaluated topical thymosin beta-4 in venous ulcer patients.
One accuracy point worth holding onto. Those trials used full-length thymosin beta-4, delivered as eye drops or applied to the skin. TB-500 is the fragment of that molecule, which gives it a credible foundation and a clear direction for the human work still to come.
The Three Sit at Very Different Evidence Levels
The three peptides in GLOW are not equally well studied, and the gap between them is wide enough to change how you read any claim made about the blend. Put side by side, the difference is hard to miss.
| Peptide | Strongest evidence available | What that supports |
|---|---|---|
| GHK-Cu | Controlled human topical studies plus measured human blood levels | Human skin and cosmetic outcomes |
| BPC-157 | 35 preclinical studies plus 1 small clinical study | Animal-model repair findings |
| TB-500 | Phase 2 human trials on the parent peptide, thymosin beta-4 | Human data on thymosin beta-4, not on TB-500 itself |
This is the part most GLOW write-ups flatten. Claims about the blend get made as though all three carry the same weight of evidence, when GHK-Cu is the only one of the three with controlled human studies on the exact molecule.
That’s a reason to be interested rather than discouraged. GHK-Cu’s human record is genuinely strong, thymosin beta-4’s trial data is real and promising, and BPC-157’s preclinical base is one of the most consistent in the peptide literature. Knowing which is which just tells you where the confident claims can honestly be made.
What You Can Take Daily, and What Stays in the Lab
GLOW stays in the research category, but two of its three peptides appear in daily supplement formulas you can buy, in oral form and at supplement-appropriate amounts. That’s the practical bridge between the search term and your routine.
BioGutPro is the closest overlap. Each serving carries BPC-157 at 1,000 mcg and GHK-Cu at 2 mg, alongside KPV, N-acetyl larazotide, CoreBiome tributyrin and zinc L-carnosine, with a sodium bicarbonate buffer. It’s built for gut lining and digestive resilience, and every amount is printed on the label.
If recovery and connective tissue are your goal instead, BioRestore is the closer match. It pairs BPC-157 arginine salt, a stabilized form chosen for oral products, with palmitoylethanolamide and hyaluronic acid.
The PEA in it earns its place. A 2023 systematic review and meta-analysis of 11 double-blind randomized controlled trials covering 774 patients found PEA reduced pain scores against comparators with a standardized mean difference of 1.68, and no major side effects were attributed to it in any of the trials.
An oral capsule is a different product from an injectable research blend, and we’re not going to pretend otherwise. What it gives you is a legitimate daily format, a printed dose, and documentation you can check before you buy.
Frequently Asked Questions
Short answers to the questions that come up most often around GLOW and its three components.
What is the GLOW peptide blend used for?
GLOW is a research preparation combining GHK-Cu, BPC-157 and TB-500, studied for tissue repair, skin remodeling, wound healing and recovery. It is supplied for laboratory research and is not a consumer supplement.
Which peptide in GLOW has the best human evidence?
GHK-Cu. It occurs naturally in human serum, its levels have been measured in patients, and controlled studies in aged skin have reported improvements in elasticity, firmness, fine lines and photodamage with topical use.
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a synthetic fragment of thymosin beta-4, the full-length human peptide. The phase 2 trial data in dry eye and chronic wounds was generated with full-length thymosin beta-4, not with TB-500.
Why are these three peptides combined?
Because each one has been studied against a different stage of tissue repair. TB-500 research centers on cell migration, BPC-157 research on fibroblast activity and connective tissue, and GHK-Cu research on collagen and elastin synthesis. No single one covers the full sequence.
Can I get GLOW’s peptides in a capsule?
Two of the three appear in oral formulas. BioGutPro contains both BPC-157 and GHK-Cu, and BioRestore contains BPC-157 arginine salt. TB-500 is not offered in a consumer capsule.
Are these peptides approved by the FDA?
No. GHK-Cu is widely used in cosmetic products, while BPC-157 and TB-500 are research compounds without FDA approval for human treatment. BPC-157 is also on the World Anti-Doping Agency prohibited list.
Read More From the BioLongevity Blog
- The Peptide Cheat Sheet: A Quick Reference by Goal
- List of Peptides and What They Do
- PEA Supplement Benefits: Recovery and Inflammatory Balance
Want the peptide science from this research in something you can actually take, with a label you can read and a dose you can check? BioRestore delivers BPC-157 arginine salt with PEA and hyaluronic acid for recovery and connective tissue support, every amount printed on the panel and every batch backed by third-party Certificates of Analysis. You can also compare the full peptide capsule collection by goal.
Ask a qualified clinician before starting any supplement if you are pregnant, nursing, taking medication, or managing a medical condition.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
References
- Dou Y, Lee A, Zhu L, Morton J, Ladiges W. The potential of GHK as an anti-aging peptide. Aging Pathobiology and Therapeutics. 2020;2(1):58-61. DOI
- Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969-988. DOI
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. 2018;19(7):1987. DOI
- Deng M, Zhang Q, Yan L, et al. Glycyl-L-histidyl-L-lysine-Cu rescues cigarette smoking-induced skeletal muscle dysfunction via a sirtuin 1-dependent pathway. Journal of Cachexia, Sarcopenia and Muscle. 2023;14(3):1365-1380. DOI
- Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal. 2025;21(4):485-495. DOI
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780. DOI
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. 2019;377(2):153-159. DOI
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta-4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012;12(1):37-51. DOI
- Sosne G, Dunn SP, Kim C. Thymosin beta-4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-496. DOI
- Kleinman HK, Sosne G. Thymosin beta-4 promotes dermal healing. Vitamins and Hormones. 2016;102:251-275. DOI
- Guarnera G, De Rosa A, Camerini R. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Annals of the New York Academy of Sciences. 2007;1112:407-412. DOI
- Lang-Illievich K, Klivinyi C, Lasser C, Brenna CTA, Szilagyi IS, Bornemann-Cimenti H. Palmitoylethanolamide in the treatment of chronic pain: a systematic review and meta-analysis of double-blind randomized controlled trials. Nutrients. 2023;15(6):1350. DOI